Canadian sanitizer firm receives NDC
This article was originally published in The Rose Sheet
Executive SummaryBritish Columbia-based Alda Pharmaceuticals receives a National Drug Code from FDA, allowing the firm to sell its OTC monograph products, including its T36 antimicrobial products, in the U.S., the firm reports April 7. "This is the first step in fulfilling our strategy of securing foreign sales for current products while we continue to pursue the testing and registration" of therapeutic products with T36, the company says. Alda's T36 technology is touted as having distinct advantages over typical alcohol hand sanitizers because it kills a "wider range" of infectious organisms and lasts for hours on skin to provide continuous protection, according to the firm
You may also be interested in...
So full of errors were the firm's online ads for its Plavinol supplement, the National Advertising Division noted support for some claims contained "many of the same flaws" as others. The prevalence of problems prompted NAD to go its "scope of review" and note unclear instructions on Plavinol labels.
Cannabidiol (CBD) represents an intriguing opportunity for cosmetics, without the statutory obstacles faced by food and dietary supplement companies. Cosmetics marketers are taking advantage, but the FDA’s recent warning letter blitz is a reminder that CBD-infused beauty products are bound by the same rules that apply to other cosmetics.